SCHEMBL9896174

SCHEMBL9896174

COCC(=O)N1CCC(NC(=O)c2c(C)[nH]c3c(-c4ccc(OC)cc4OCC4CC4)ncnc23)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TBK1 Q9UHD2 2/20 0.39
PAK1 Q13153 1/20 0.36
HPGDS O60760 1/20 0.36
PIK3CD O00329 1/20 0.36
PIK3CA P42336 1/20 0.36
LMNA P02545 3/20 0.35
MAPT P10636 3/20 0.35
KDM4E B2RXH2 2/20 0.35
ALDH1A1 P00352 2/20 0.35
HPGD P15428 2/20 0.35
USP2 O75604 1/20 0.35
HSD17B10 Q99714 1/20 0.35
EPHX2 P34913 1/20 0.35
BTK Q06187 1/20 0.35
POLB P06746 2/20 0.34
MAPK1 P28482 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
GRIN1 Q05586 1/20 0.34
GRIN2B Q13224 1/20 0.34
KMT2A Q03164 5/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9897983 0.96 TBK1 (0.37) TBK1PAK1HPGDSPIK3CDPIK3CA
SCHEMBL9897342 0.95 TBK1 (0.43) TBK1PAK1HPGDSLMNAMAPT
SCHEMBL9895486 0.94 TBK1 (0.39) TBK1PAK1HPGDSPIK3CDPIK3CA
SCHEMBL9895357 0.94 EPHX2 (0.42) TBK1PAK1HPGDSLMNAMAPT
SCHEMBL1439111 0.92 HSD17B10 (0.38) PIK3CDPIK3CALMNAHSD17B10BTK
SCHEMBL9897140 0.92 HPGDS (0.44) TBK1PAK1HPGDSLMNAMAPT
SCHEMBL16224202 0.92 PAK1 (0.37) TBK1PAK1HPGDSLMNAMAPT
SCHEMBL9897834 0.91 TBK1 (0.41) TBK1PAK1HPGDSLMNAMAPT
SCHEMBL9898313 0.90 TBK1 (0.37) TBK1PAK1HPGDSPIK3CDPIK3CA
SCHEMBL9897236 0.90 EPHX2 (0.37) TBK1PIK3CDPIK3CAEPHX2BTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2470536-B1 Methylpyrrolopyrimidinecarboxamides TAKEDA GMBH (DE) 2014-11-12 EP claimed
US-9376442-B2 Methylpyrrolopyrimidinecarboxamides TAKEDA GMBH (DE) 2016-06-28 US disclosed
US-20150073001-A1 METHYLPYRROLOPYRIMIDINECARBOXAMIDES ASTRAZENECA AB (SE) 2015-03-12 US disclosed
US-8927557-B2 Methylpyrrolopyrimidinecarboxamides TAKEDA GMBH (DE) 2015-01-06 US disclosed
EP-2470536-B1 Methylpyrrolopyrimidinecarboxamides TAKEDA GMBH (DE) 2014-11-12 EP disclosed
US-20120149721-A1 METHYLPYRROLOPYRIMIDINECARBOXAMIDES NYCOMED GMBH (DE) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149721-A1 METHYLPYRROLOPYRIMIDINECARBOXAMIDES PDE5A, PDE12, PDE4A TBK1 3747/4885PAK1 1904/4885HPGDS 1143/4885
US-20150073001-A1 METHYLPYRROLOPYRIMIDINECARBOXAMIDES PDE12, PDE5A, PDE4A TBK1 3270/4885PAK1 1610/4885HPGDS 982/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.